Ad5CMVDre (Standard Titer): Adenoviral vector with CMV (Cytomegalovirus) promoter driving the expression of the Dre Recombinase protein. Titer range 1x10^10 to 7x10^10 pfu/ml.

A patent on Dre recombinase has been assigned to the Stowers Institute, inventors Sauer and McDermott; United States Patent 7422889. The Viral Vector Core has been issued permission to distribute the technology in line with the position of the Stower Institute:

‘The Stowers Institute considers the sharing of research materials to be an essential aspect of scientific citizenship. In the specific case of dre-rox technology, the Institute owns certain intellectual property, including an issued patent and a pending patent application covering, among other things, “Dre recombinase and recombinase systems employing Dre recombinase.” The Institute will allow non-profit organizations to make or use material covered by the Institute’s dre-rox intellectual property for non-commercial purposes under terms no more onerous than those contained in the Uniform Biological Material Transfer Agreement. The Institute’s policy is to offer for-profit organizations a non-exclusive license (without reach-through royalties) to make or use material covered by the Institute’s dre-rox intellectual property for internal research purposes. For other uses by for-profit organizations, the Institute will evaluate requests on a case-by-case basis.’

Ad5mCD14-Cre